Pathways of hepatic and renal damage through non-classical activation of the renin-angiotensin system in chronic liver disease
- PMID: 31580514
- DOI: 10.1111/liv.14272
Pathways of hepatic and renal damage through non-classical activation of the renin-angiotensin system in chronic liver disease
Abstract
In liver cirrhosis, renin-angiotensin system (RAS) activation sustains renal sodium retention and hepatic fibrogenesis. New information has recently enlivened the traditional concept of RAS. For instance, renin and prorenin bind their ubiquitous receptors, resulting in the local production of angiotensin (Ang) II; increased serum calcium and calcimimetic agents, through stimulation of extracellular calcium-sensing receptors (CaSR), blunt renin production and lead to natriuretic effects in human and experimental cirrhosis. Alongside systemic production, there is Ang II tissue production within various organs through RAS enzymes different from angiotensin-converting enzyme (ACE), that is chymase, tissue plasminogen activator and several cathepsins. In experimental cirrhosis, inhibition of chymase leads to natriuretic and hepatic antifibrotic effects, without changes in systemic haemodynamics. In the kidney, local RAS coordinates proximal and distal tubular sodium reabsorption. However, renalase, whose plasma and tissue levels are severely altered in experimental cirrhosis, degrades systemic and renal tubule catecholamines, antagonizing the effects of renal RAS. Angiotensinogen-derived natriuretic and vasodilating peptides (Ang1-9, Ang1-7, Ang3-8) and their receptors have been described. Receptor agonists or antagonists are available to affect portal hypertension and sodium retention in cirrhosis. ACE2-dependent generation of Ang1-7 may inhibit experimental liver fibrosis. inhibition of Ang1-7 clearance by means of neprilysin blockade has portal hypotensive and natriuretic effects. Ang1-12, whose production renin does not regulate, is converted to several different angiotensin peptides via chymase. Finally, Ang II behaves as either an antinatriuretic or a natriuretic agent, based on the tissue content of AT1 R and AT2 R receptors, their ratio being prone to pharmacological modulation.
Keywords: liver cirrhosis; liver fibrosis; renin angiotensin system; sodium retention.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
Recent Updates on the Proximal Tubule Renin-Angiotensin System in Angiotensin II-Dependent Hypertension.Curr Hypertens Rep. 2016 Aug;18(8):63. doi: 10.1007/s11906-016-0668-z. Curr Hypertens Rep. 2016. PMID: 27372447 Free PMC article. Review.
-
Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension.Korean J Intern Med. 2018 May;33(3):453-461. doi: 10.3904/kjim.2017.317. Epub 2018 Feb 21. Korean J Intern Med. 2018. PMID: 29462546 Free PMC article. Review.
-
New Viral Diseases and New Possible Remedies by Means of the Pharmacology of the Renin-Angiotensin System.J Renin Angiotensin Aldosterone Syst. 2023 Jul 12;2023:3362391. doi: 10.1155/2023/3362391. eCollection 2023. J Renin Angiotensin Aldosterone Syst. 2023. PMID: 37476705 Free PMC article. Review.
-
The intrarenal renin-angiotensin system in hypertension.Adv Chronic Kidney Dis. 2015 May;22(3):204-10. doi: 10.1053/j.ackd.2014.11.004. Adv Chronic Kidney Dis. 2015. PMID: 25908469 Review.
-
Is the renin-angiotensin system actually hypertensive?Pediatr Nephrol. 2014 Jun;29(6):951-60. doi: 10.1007/s00467-013-2481-0. Epub 2013 Jun 6. Pediatr Nephrol. 2014. PMID: 23740033 Review.
Cited by
-
Transplantation of human umbilical cord-derived mesenchymal stem cells improves age-related ovarian functional decline via regulating the local renin-angiotensin system on inflammation and oxidative stress.Stem Cell Res Ther. 2024 Oct 23;15(1):377. doi: 10.1186/s13287-024-03997-6. Stem Cell Res Ther. 2024. PMID: 39444026 Free PMC article.
-
Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: A comparative review.Front Pharmacol. 2023 Feb 13;14:1101068. doi: 10.3389/fphar.2023.1101068. eCollection 2023. Front Pharmacol. 2023. PMID: 36860293 Free PMC article. Review.
-
Effects of renin-angiotensin inhibitors on renal function and the clinical course in patients with decompensated cirrhosis.Sci Rep. 2023 Oct 14;13(1):17486. doi: 10.1038/s41598-023-44299-w. Sci Rep. 2023. PMID: 37838780 Free PMC article.
-
An impaired pituitary-adrenal signalling axis in stable cirrhosis is linked to worse prognosis.JHEP Rep. 2023 May 11;5(8):100789. doi: 10.1016/j.jhepr.2023.100789. eCollection 2023 Aug. JHEP Rep. 2023. PMID: 37484210 Free PMC article.
-
A Golden Shield: The Protective Role of Curcumin against Liver Fibrosis.Curr Med Chem. 2025;32(10):1987-2004. doi: 10.2174/0929867331666230821095329. Curr Med Chem. 2025. PMID: 37605399 Review.
References
REFERENCES
-
- Tigerstedt R, Bergman PG. Niere eine kreilauf. Scand Arch Physiol. 1898;8:223-227.
-
- Prinzmetal M, Lewis HA, Leo SD. The etiology of hypertension due to complete renal ischemia. J Exp Med. 1940;72:763-776.
-
- Braun-Menendez E, Fasciolo JC, Leloir LF, Muñoz JM. The substance causing renal hypertension. J Physiol. 1940;98:283-298.
-
- Bumpus FM, Green AA, Page IH. Purification of angiotonin. J Biol Chem. 1954;210:287-294.
-
- Simpson SA, Tait JF, Wettstein A, et al. Constitution of aldosterone, a new mineralocorticoid. Experientia. 1954;10:132-133.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous